Biomarkers predictive of predisposition to depression and response to treatment

• US 10,544,462 B2
• Filed: 10/06/2017
• Issued: 01/28/2020
• Est. Priority Date: 01/17/2014
• Status: Active Grant

• Current Assignee: Northwestern University
• Original Assignee: Northwestern University
• Inventors: Redei, Eva E.
• Primary Examiner(s): Haney, Amanda
• Application Number:
  US15/727,179
• Publication Number:
  US 20180030539A1
• Time in Patent Office: 844 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays

Abstract

The present invention relates generally to the identification of subjects with a predisposition to recurrent depression, predicting a subject'"'"'s responsiveness to therapy, and determining whether a subject has remitted from depression following therapy. In particular, provided herein are biomarkers, methods, and kits for such uses.

Claims

1. A panel of biomarkers consisting of an isolated set of 100 or fewer full-length cDNA biomarkers, wherein said isolated set comprises CTTNBP2, DAG1, and NTRK2 full-length cDNA biomarkers.

2. The panel of biomarkers of claim 1, further comprising a RAB27B full-length cDNA biomarker.

3. The panel of biomarkers of claim 1, further comprising a OTX2 full-length cDNA biomarker.

4. The panel of biomarkers of claim 1, further comprising DRD2, OSBPL2, and DPPA3 full-length cDNA biomarkers.

5. The panel of biomarkers of claim 1, further comprising LIX1 and SLC24A4 full-length cDNA biomarkers.

6. The panel of biomarkers of claim 1, further comprising OSBPL2and DPPA3 full-length cDNA biomarkers.

7. The panel of biomarkers of claim 1, further comprising DRD2, LIX1 and SLC24A4 full-length cDNA biomarkers.

8. The panel of biomarkers of claim 1, further comprising OSBPL2, SLC24A4, and DPPA3 full-length cDNA biomarkers.

9. The panel of biomarkers of claim 1, further comprising DRD2 and LIX1 full-length cDNA biomarkers.

10. The panel of biomarkers of claim 1, further comprising DRD2, OSBPL2, OTX2, DPPA3, RAB27B, LIX1, and SLC24A4 full-length cDNA biomarkers.